Johnson & Johnson : WSJ BLOG/Health : A.M. Vitals: J&J Nears Settlement With Justice Dept.
06/21/2012| 08:13am US/Eastern
Recommend:
(This story has been posted on The Wall Street Journal Online's Health Blog at http://blogs.wsj.com/health.)
By Stefanie Ilgenfritz
Here's what's making health news this morning:
J&J Close to Settling Off-Label Probes (WSJ): Johnson & Johnson and Justice are close to settling a protracted investigation into promotion of the antipsychotic Risperdal, for what would be one of the highest sums to date in a drug-marketing case, according to people familiar with the matter. The sides are trying to wrap together lawsuits, state investigations and other probes, and are discussing a payment of at least $1.5 billion, some of the people said.
FDA Panel Backs Onyx Pharmaceuticals Cancer Drug (WSJ): The company is seeking FDA approval of the product to treat patients with multiple myeloma, a cancer that affects the bone marrow, who have failed at least two other treatments.
Health-Care Tax Credit Eludes Some (WSJ): Hundreds of thousands of small businesses are excluded from claiming a health-care tax credit, and many blame overly narrow restrictions.
Not Just Insurance Is at Stake (WSJ): Chain restaurants, tanning salons, breast-feeding advocacy groups and others far afield of health care have a lot riding on whether the law stays in place.
House Passes FDA User Fee Reauthorization (WSJ): The House on Wednesday passed a bill to let the Food and Drug Administration collect about $6 billion in user fees from medical companies to help fund the agency.
Stress Disorder Seen More After Heart Attack (NY Times): The emotional toll of a heart attack can be so severe that an estimated 1 in 8 patients who survive the experience develop post traumatic stress disorder, a condition that doubles the risk of dying of a second heart attack, according to new research.
-For continuously updated news from The Wall Street Journal, see WSJ.com at http://wsj.com.
Recommend :
